Table 1: Pre-operative characteristics of BPD-DS surgery women

From: Acylation stimulating protein reduction precedes insulin sensitization after BPD-DS bariatric surgery in severely obese women

Demographics and treatment3222P
Age (years)38.3±10.342.0±10.6NS
Diabetic medication (%)0/32 (0%)20/22 (91%)<0.001
Lipid medication4/32 (13%)18/22 (82%)<0.001
Body composition
 BMI (kg m−2)48.6±7.449.8±7.9NS
 Fat mass (kg)66.9±13.566.2±14.8NS
 Lean mass (kg)59.3±8.161.0±9.5NS
 Fat percentage (%)52.8±2.651.7±3.6NS
Biochemical measures
 ASP (nmol l−1)30.0±15.738.4±21.0<0.05
 C3 (mg dl−1)1.99±0.342.09±0.4NS
 hsCRP (mg dl−1)14.1±24.210.8±8.1NS
 Glucose (mmol dl−1)5.76±1.678.28±3.28<0.001
 HbA1c (%)5.62±0.886.81±1.03<0.001
 Insulin (pmol l−1)149±71193±119 
 Fructosamine (μmol l−1)202±33230±47<0.01
Lipid parameters
 TG (mmol l−1)1.38±0.571.81±0.82<0.05
 Cholesterol (mmol l−1)4.80±0.684.53±1.04NS
 HDL-Chol (mmol l−1)1.40±0.301.26±0.35NS
 LDL-Chol (mmol l−1)2.78±0.592.45±0.77NS
 Apo-B (mmol l−1)0.79±0.160.75±0.20NS
 NEFA (mmol l−1)0.55±0.120.53±0.17NS
  1. Abbreviations: ASP acylation stimulating protein; BMI, body mass index; Chol, cholesterol; hsCRP, high-sensitivity C-reactive protein; NEFA, non-esterified fatty acid; TG, triglyceride; The values are presented as mean±s.d. and significant differences analyzed by Student’s t-test for non-diabetic women vs diabetic women where pNS indicates not significant. For diabetic and lipid lowering medication, results were analyzed by χ2.